Literature DB >> 11214627

Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas.

T Iuchi1, N Saeki, K Osato, A Yamaura.   

Abstract

Surgical cure of growth hormone producing pituitary adenomas (GHomas) becomes difficult when they invade the cavernous sinus (CS). Tumour proliferative activity and angiogenesis are thought to be required for tumour growth and invasion, and vascular endothelial growth factor (VEGF) activates neovascularization around tumours. In this study, the mechanism and clinical significance of CS invasion is analysed. In 25 surgically treated GHomas, the extent of CS invasion was classified as high (Knosp's grade 3 and 4), and low (grade 0, 1 and 2) MR grades, and the MR grades were compared with tumour proliferative potential (Ki-67 expression), angiogenetic demand (VEGF expression), volume of adenomas and serum hormone levels. The Ki-67 index of high MR grade adenomas (1.17 +/- 0.62%) was significantly higher than that of low MR grade adenomas (0.55 +/- 0.42%, p = 0.027), whereas VEGF expression showed no significant correlation with MR grades (p > 0.999). Tumour volume also showed a significant correlation with MR grade (p = 0.002). VEGF expression was not correlated with serum hormone level and volume, but was correlated with tumour proliferative potential. Proliferative potential and tumour volume were two independent factors related to CS invasion. Although VEGF expression was not a direct factor related to CS invasion, it may indirectly play a role in activation of tumour aggressiveness, which is required in CS invasion. Our results show that high MR grade adenomas have higher proliferative ability. In order to improve the surgical outcome, preoperative medical debulking is indicated, particularly, in such adenomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11214627     DOI: 10.1007/s007010070003

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  8 in total

1.  The clinical significance of MIB-1 labeling index in pituitary adenomas.

Authors:  Geeta Chacko; Ari G Chacko; Kalman Kovacs; Bernd W Scheithauer; Sunithi Mani; J P Muliyil; M S Seshadri
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

2.  VEGF and CD31 association in pituitary adenomas.

Authors:  Carolina Cristina; María Inés Perez-Millan; Guillermina Luque; Raúl Ariel Dulce; Gustavo Sevlever; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

3.  Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence.

Authors:  Ruth Sánchez-Ortiga; Laura Sánchez-Tejada; Oscar Moreno-Perez; Pedro Riesgo; Maria Niveiro; Antonio M Picó Alfonso
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

4.  Gamma Knife robotic microradiosurgery of pituitary adenomas invading the cavernous sinus: treatment concept and results in 89 cases.

Authors:  Motohiro Hayashi; Mikhail Chernov; Noriko Tamura; Mariko Nagai; Shoji Yomo; Taku Ochiai; Kosaku Amano; Masahiro Izawa; Tomokatsu Hori; Yoshihiro Muragaki; Hiroshi Iseki; Yoshikazu Okada; Kintomo Takakura
Journal:  J Neurooncol       Date:  2010-04-22       Impact factor: 4.130

5.  Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.

Authors:  Maliheh Ghadir; Mohammad E Khamseh; Mahshid Panahi-Shamsabad; Mohammad Ghorbani; Hamideh Akbari; Ali Zare Mehrjardi; Maryam Honardoost; Bahram Jafar-Mohammadi
Journal:  Endocrine       Date:  2020-07-12       Impact factor: 3.633

6.  Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas.

Authors:  Koji Takada; Shozo Yamada; Akira Teramoto
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

7.  Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial.

Authors:  Rob A Vergeer; Mark R Postma; Jos M A Kuijlen; Gerrit van den Berg; Iris Schmidt; Astrid Gw Korsten-Meijer; Robert A Feijen; Schelto Kruijff; Wouter B Nagengast; J Marc C van Dijk; Wilfred F A den Dunnen; André P van Beek
Journal:  BMJ Open       Date:  2021-10-07       Impact factor: 2.692

8.  Associations of Ki-67 Labeling Index with Clinical and Paraclinical Features of Growth Hormone-Secreting Pituitary Adenomas: A Single Center Report from Iran.

Authors:  Shahrzad Mohseni; Maryam Aboeerad; Farshad Sharifi; Seyed Mohammad Tavangar; Mohammadreza Mohajeri-Tehrani
Journal:  Int J Endocrinol Metab       Date:  2019-04-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.